Mark Wilhelmus Dirk Sweep
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Wilhelmus Dirk Sweep has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Kalijn Fredrike Bol
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications Alastair B Hansen
Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark
1 shared publicationAnders Toxvaerd
Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark
1 shared publicationAne Soegaard Teisner
Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark
1 shared publication- Benno Küsters
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication - Carla Marie Louise van Herpen
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
Spatial clustering of tumor-infiltrating lymphocytes in symptomatic melanoma brain metastases
- 17 September 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
Open AccessSpatial clustering of tumor-infiltrating lymphocytes in symptomatic melanoma brain metastases
- Open Access
- 5 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013861
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
Background: Immune-related hepatitis (ir-hepatitis) ranks among the most frequent adverse events of immune checkpoint inhibitors (ICIs). Limited knowledge exists regarding the incidence, characteristics, and treatment of patients having an inadequate response to initial therapy with steroids. Characterizing ir-hepatitis phenotypes and treatment responses can provide valuable insights for guiding treatment decisions and prognosis. Methods: This is a prospective study including patients treated with ICIs experiencing grade 3–4 ir-hepatitis. All patients received methylprednisolone 2 mg/kg for at least 72 hours and underwent liver biopsy. Ursodeoxycholic acid was added in mixed and cholestatic drug-induced liver injury (DILI) phenotypes, and mycophenolate mofetil (MMF) was added in patients with inadequate response to steroids. Multiplex immunohistochemistry (mIHC) for CD3, CD8, FoxP3, CD20, and CD56/NKp46 was used on liver biopsies, and single-cell RNA sequencing of peripheral blood samples was employed to characterize the immunological response. Results: A total of 34 patients with ir-hepatitis were included, of which 20 patients (59%) responded to steroids. Six patients (18%) were steroid-unresponsive and needed MMF. Eight patients (23%) had steroid-dependent ir-hepatitis; they had an initial response to steroids but relapsed during tapering. Patients with steroid-unresponsive and steroid-dependent ir-hepatitis were treated with significantly higher accumulated steroid doses. Alcohol consumption and male sex were significantly related to inadequate response to steroids. Patients with mixed DILI had the highest steroid response rates (72%), while only half of the patients with hepatocellular and cholestatic DILI responded. Patients with cholestatic DILI had the worst prognosis concerning management of ir-hepatitis, risk of cancer progression and death. MIHC of liver biopsies revealed significantly increased T cell infiltration in ir-hepatitis, including cytotoxic, helper and regulatory T cells. Single-cell RNA sequencing of blood samples showed CD8+ effector T cell clonal expansion in a patient with steroid-unresponsive ir-hepatitis than in a steroid responder. Conclusion: Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis. Trial registration number: ClinicalTrials.gov ID number NCT04810156 and EudraCT no. 2020-004483-26.
- 5 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013861
Open AccessProspective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
Background: Immune-related hepatitis (ir-hepatitis) ranks among the most frequent adverse events of immune checkpoint inhibitors (ICIs). Limited knowledge exists regarding the incidence, characteristics, and treatment of patients having an inadequate response to initial therapy with steroids. Characterizing ir-hepatitis phenotypes and treatment responses can provide valuable insights for guiding treatment decisions and prognosis. Methods: This is a prospective study including patients treated with ICIs experiencing grade 3–4 ir-hepatitis. All patients received methylprednisolone 2 mg/kg for at least 72 hours and underwent liver biopsy. Ursodeoxycholic acid was added in mixed and cholestatic drug-induced liver injury (DILI) phenotypes, and mycophenolate mofetil (MMF) was added in patients with inadequate response to steroids. Multiplex immunohistochemistry (mIHC) for CD3, CD8, FoxP3, CD20, and CD56/NKp46 was used on liver biopsies, and single-cell RNA sequencing of peripheral blood samples was employed to characterize the immunological response. Results: A total of 34 patients with ir-hepatitis were included, of which 20 patients (59%) responded to steroids. Six patients (18%) were steroid-unresponsive and needed MMF. Eight patients (23%) had steroid-dependent ir-hepatitis; they had an initial response to steroids but relapsed during tapering. Patients with steroid-unresponsive and steroid-dependent ir-hepatitis were treated with significantly higher accumulated steroid doses. Alcohol consumption and male sex were significantly related to inadequate response to steroids. Patients with mixed DILI had the highest steroid response rates (72%), while only half of the patients with hepatocellular and cholestatic DILI responded. Patients with cholestatic DILI had the worst prognosis concerning management of ir-hepatitis, risk of cancer progression and death. MIHC of liver biopsies revealed significantly increased T cell infiltration in ir-hepatitis, including cytotoxic, helper and regulatory T cells. Single-cell RNA sequencing of blood samples showed CD8+ effector T cell clonal expansion in a patient with steroid-unresponsive ir-hepatitis than in a steroid responder. Conclusion: Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis. Trial registration number: ClinicalTrials.gov ID number NCT04810156 and EudraCT no. 2020-004483-26.